Snail1 as a key prognostic biomarker of cancer-associated fibroblasts in breast tumors

  • 0Cancer Research Program, associated unit IIBB-CSIC, Hospital del Mar Research Institute, Barcelona, Spain.

Summary

This summary is machine-generated.

Cancer-associated fibroblasts (CAFs) heterogeneity impacts treatment. This review highlights Snail1-expressing CAFs and a novel gene signature for predicting prognosis in breast and other solid tumors.

Area Of Science

  • Oncology
  • Cancer Biology
  • Fibroblast Research

Background

  • Accurate cancer diagnosis is vital for effective treatment selection, but current methods often misclassify patients, leading to ineffective therapies.
  • Cancer-associated fibroblasts (CAFs) are key players in tumor progression, and their biomarkers offer significant prognostic value.
  • CAF populations exhibit substantial heterogeneity, with distinct subtypes associated with various cancer types and disease stages.

Purpose Of The Study

  • To review recent findings on CAF heterogeneity in breast cancer.
  • To identify gene signatures defining CAF subtypes and predicting prognosis using single-cell RNA sequencing.
  • To explore the role of the transcription factor Snail1 in CAF-associated malignancy.

Main Methods

  • Analysis of patient samples and mouse models of breast cancer.
  • Application of single-cell RNA sequencing to identify CAF subtypes and gene signatures.
  • Investigation of genes and pathways regulated by Snail1 in CAFs.

Main Results

  • Identification of distinct CAF subtypes with prognostic potential based on gene signatures.
  • Demonstration of the fibrotic and immunosuppressive roles of Snail1-expressing fibroblasts.
  • Unveiling of a streamlined Snail1-related gene signature in CAFs with prognostic value.

Conclusions

  • CAF heterogeneity is critical for understanding cancer progression and prognosis.
  • Snail1-expressing CAFs contribute to tumor malignancy through fibrotic and immunosuppressive mechanisms.
  • A novel Snail1-related gene signature in CAFs shows promise for predicting outcomes in breast and other solid tumors.